Search Within

Gregory J Riely

Formats
  1. Journal Article (295)
  2. Meeting Abstract (265)
  3. Book Section (16)
  4. Guidelines (15)
  5. Conference Paper (4)
  6. Review (4)
  7. Editorial (3)
  8. Book Whole (1)
  9. Correspondence (1)
  10. Research Letter (1)
Groups
  1. Department of Medicine (605)
  2. Solid Tumor Oncology Division (605)
  3. Thoracic Oncology (605)
  4. Department of Pathology and Laboratory Medicine (262)
  5. GSK Faculty (248)
  6. Human Oncology and Pathogenesis Program (223)

More Groups

People
  1. Mark Kris (222)
  2. Marc Ladanyi (188)
  3. Helena Yu (108)
  4. Maria Arcila (85)
  5. Vincent Miller (79)
  6. Charles Rudin (76)

More People

Years
  1. 2025 (9)
  2. 2024 (25)
  3. 2023 (45)
  4. 2022 (39)
  5. 2021 (41)
  6. 2020 (29)

More Years

Publications
  1. Journal of Clinical Oncology (157)
  2. Journal of Thoracic Oncology (113)
  3. Clinical Cancer Research (46)
  4. Annals of Oncology (32)
  5. Journal of the National Comprehensive Cancer Network (26)
  6. Cancer Research (14)

More Publications

Publishers
  1. American Society of Clinical Oncology (175)
  2. Elsevier Inc. (137)
  3. American Association for Cancer Research (77)
  4. Oxford University Press (39)
  5. Harborside Press (26)
  6. Elsevier Science, Inc. (23)

More Publishers

Results (605)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase II study of HSP90 inhibitor AUY922 and erlotinib (E) for patients (pts) with EGFR-mutant lung cancer and acquired resistance (AR) to EGFR tyrosine kinase inhibitors (EGFR TKIs)
    Meeting Abstract

    Johnson, M. L.; Hart, E. M.; Rademaker, A.; Weitner, B. B.; Urman, A.; Simm, H. D.; Fountas, L. M.; Worden, R.; Patel, J. D.; Miller, V. A.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • A retrospective analysis of the prevalence of EGFR or KRAS mutations in patients (pts) with crizotinib-naive and crizotinib-resistant, ALK-positive non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Gainor, J. F.; Varghese, A. M.; Ou, S. H. I.; Kabraji, S.; Awad, M. M.; Katayama, R.; Pawlak, A.; Mino-Kenudson, M.; Yeap, B. Y.; Riely, G. J.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Screening for RET and ROS1 fusions in an enriched cohort of pan-negative never-smokers with advanced lung adenocarcinomas to identify patients for treatment in targeted therapy trials
    Meeting Abstract

    Drilon, A. E. D.; Wang, L.; Hasanovic, A.; Joubert, P.; Kris, M. G.; Riely, G. J.; Ladanyi, M.; Rizvi, N. A.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • A phase II study of HSP90 inhibitor AUY922 and erlotinib (E) in patients (PTS) with EGFR-mutant lung cancer and acquired resistance (AR) to EGFR tyrosine kinase inhibitors (EGFR TKIS)
    Meeting Abstract

    Yu, H. A.; Johnson, M. L.; Urman, A.; Rademaker, A.; Hart, E.; Weitner, B. B.; Patel, J. D.; Kris, M.; Riely, G.
    Journal of Thoracic Oncology (2013)

    Fulltext@MSK | Save
  • Comparison of the characteristics and clinical course of patients with metastatic KRAS mutant lung cancers
    Meeting Abstract

    Riely, G.; Yu, H. A.; Sima, C. S.; Shen, R. L.; Kass, S. L.; Kris, M. G.; Ladanyi, M.
    Journal of Thoracic Oncology (2013)

    Fulltext@MSK | Save
  • Prospective molecular evaluation of small cell lung cancer (SCLC) utilizing the comprehensive mutation analysis Program at Memorial Sloan-Kettering Cancer Center (MSKCC)
    Meeting Abstract

    Pietanza, M. C.; Varghese, A.; Won, H.; Rekhtman, N.; Wang, L.; Travis, W. D.; Paik, P. K.; Riely, G. J.; Zakowski, M. F.; Ladanyi, M.; more...
    Journal of Thoracic Oncology (2013)

    Fulltext@MSK | Save
  • Clinical benefit of continuing crizotinib beyond initial disease progression in patients with advanced ALK-positive non-small-cell lung cancer
    Meeting Abstract

    Ou, S. H. I.; Riely, G. J.; Tang, Y. Y.; Kim, D. W.; Otterson, G. A.; Crino, L.; Bartlett, C. H.; Cohen, D. P.; Clark, J. W.; Jänne, P. A.
    Journal of Thoracic Oncology (2013)

    Fulltext@MSK | Save
  • Crizotinib therapy for patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Ou, S. H. I.; Kim, D. W.; Camidge, D. R.; Riely, G.; Salgia, R.; Shapiro, G.; Solomon, B.; Engelman, J. A.; Kwak, E. L.; Clark, J. W.; more...
    Journal of Thoracic Oncology (2013)

    Fulltext@MSK | Save
  • Consistent therapeutic efficacy of CH5424802/RO5424802 in brain metastases among crizotinib-refractory ALK-positive non-small cell lung cancer (NSCLC) patients in an ongoing phase I/II study (AF-002JG/NP28761, NCT01588028)
    Meeting Abstract

    Ou, S. H. I.; Gadgeel, S.; Chiappori, A. A.; Gandhi, L.; Azada, M.; Garcia, L.; Takaya, I.; Yokoyama, S.; Kamei, T.; Tanaka, T.; more...
    Journal of Thoracic Oncology (2013)

    Fulltext@MSK | Save
  • Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma
    Meeting Abstract

    Gerber, N. K.; Yamada, Y.; Shi, W. J.; Zhang, Z. G.; Riely, G.; Beal, K.; Yu, H. A.; Chan, T. A.; Rimner, A.; Wu, A. J.
    Journal of Thoracic Oncology (2013)

    Fulltext@MSK | Save